Mereo BioPharma Group plc MREO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 43.29% | 24.33% | 3.18% | 8.26% | -- |
| Total Depreciation and Amortization | 5.43% | 9.33% | 5.61% | -24.11% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.06% | -34.21% | 33.62% | -53.12% | -- |
| Change in Net Operating Assets | 63.74% | -184.75% | -768.02% | 97.00% | -- |
| Cash from Operations | 23.00% | 18.74% | 5.67% | -8.30% | -- |
| Capital Expenditure | 100.00% | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 100.00% | 100.00% | 100.00% | -- |
| Cash from Investing | 100.00% | 100.00% | 97.14% | 97.14% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.99% | -99.92% | -98.88% | -98.96% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 85.40% | 76.67% | 70.60% | -- |
| Cash from Financing | 111.27% | -100.20% | -99.29% | -99.46% | -- |
| Foreign Exchange rate Adjustments | -130.72% | 5.91% | 895.71% | -75.75% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.93% | -289.97% | -332.70% | -276.87% | -- |